BMY · Bristol Myers Squibb Company
AI read · Neutral
The AI's read
FDA granted accelerated approval to BMY's Zenbexus (iberdomide) for adult multiple myeloma in combination ZDd. The drug is the first FDA-approved CELMoD and showed 41% MRD-negative CR versus 21% in Phase 3. The market has moved -1.19% since the news and BMY's RSI sits at 69.36, so some upside may be priced or met with skepticism. Pricing cited at roughly $29,500 per 28-day cycle plus the need for confirmatory trials likely explains the muted reaction. We lean bullish: approval, first-in-class status, and deep response data create real revenue optionality. Conviction 84% because confirmatory data and payer pushback are real risks that can add volatility and cap near-term upside.